| 2024-04-23 |
Lisata Therapeutics, Inc. |
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma lisata.com ↗ |
| 2024-04-09 |
Lisata Therapeutics, Inc. |
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma lisata.com ↗ |
| 2024-03-21 |
Lisata Therapeutics, Inc. |
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma lisata.com ↗ |
| 2024-01-17 |
Lisata Therapeutics, Inc. |
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme lisata.com ↗ |
| 2024-01-04 |
Lisata Therapeutics, Inc. |
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy lisata.com ↗ |
| 2023-12-12 |
Lisata Therapeutics, Inc. |
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma lisata.com ↗ |
| 2023-10-24 |
Lisata Therapeutics, Inc. |
Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide lisata.com ↗ |
| 2023-10-17 |
Lisata Therapeutics, Inc. |
Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer lisata.com ↗ |
| 2023-09-12 |
Lisata Therapeutics, Inc. |
Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors lisata.com ↗ |
| 2023-09-06 |
Lisata Therapeutics, Inc. |
Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma lisata.com ↗ |
| 2023-08-08 |
Lisata Therapeutics, Inc. |
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma lisata.com ↗ |
| 2023-05-24 |
Lisata Therapeutics, Inc. |
Lisata Therapeutics Announces Enhancements to Ongoing Phase 2b ASCEND Trial of LSTA1 lisata.com ↗ |
| 2023-04-18 |
Lisata Therapeutics, Inc. |
Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma lisata.com ↗ |
|